Cataract Clinical Trials Analysis 2025: Topical Small Molecules, Regenerative Therapies, and Next-Gen IOLs Aim to Delay or Replace Surgical Intervention | DelveInsight

DelveInsight's "Cataract - Clinical Trials Analysis, 2025" highlights a shifting development landscape aiming to complement or reduce reliance on surgery through pharmacologic, regenerative, and device-based innovations.

Emerging programs explore topical lanosterol and oxysterol derivatives, antioxidants, and crystallin stabilizers designed to prevent or reverse lens opacity. Early-phase data show potential for improved lens transparency and visual acuity, though no approved pharmacologic therapy exists yet.

Parallel advances in lens regeneration and drug-eluting intraocular lenses (IOLs) target restoration of native lens clarity and prevention of postoperative complications.

Late-stage studies increasingly pair functional vision endpoints with objective lens densitometry to demonstrate both structural and clinical benefit-signaling a new phase of innovation that could redefine cataract management over the next decade.

Interested in learning more about the current treatment landscape and the key drivers shaping the cataract pipeline? Click here: https://www.delveinsight.com/report-store/cataract-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Cataract Pipeline Report
• DelveInsight's cataract pipeline analysis depicts a strong space with 5+ active players working to develop 5+ pipeline drugs for cataract treatment.
• The leading cataract companies include Nacuity Pharmaceuticals, CGeneTech, Melt Pharmaceuticals, Plex Pharmaceuticals, and others are evaluating their lead assets to improve the cataract treatment landscape.
• Key cataract pipeline therapies in various stages of development include NPI 002, CGT 1507, Research programme: ocular therapeutics, and others.
• In May 2025, Atia Vision, a Shifamed portfolio company, received FDA IDE approval to begin a feasibility study of its OmniVuTM Lens System-an innovative intraocular lens aimed at restoring dynamic vision after cataract surgery, surpassing current presbyopia-correcting lenses.
• In March 2025, Bausch + Lomb (NYSE/TSX: BLCO) voluntarily recalled its enVista intraocular lenses following reports of unexplained complications.
• In November 2024, Melt Pharmaceuticals announced positive topline results from its Phase III trial of MELT-300, a non-IV, non-opioid sedation tablet for cataract surgery, meeting FDA-agreed criteria for regulatory submission.
• In June 2024, Alcon (SIX/NYSE: ALC) announced that its UNITY® Vitreoretinal Cataract System (VCS) and UNITY® Cataract System (CS) received FDA 510(k) clearance, marking the first innovations from its Unity portfolio.

Request a sample and discover the recent breakthroughs happening in the cataract pipeline landscape @ https://www.delveinsight.com/report-store/cataract-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Cataract Overview
Cataracts are a common eye condition characterized by the clouding of the eye's natural lens, leading to blurred vision and difficulty seeing clearly. They develop gradually, often due to aging, but can also result from factors like diabetes, trauma, or prolonged exposure to UV light. Symptoms include faded colors, glare, halos around lights, and difficulty with night vision. Diagnosis is made through a comprehensive eye exam. While early cataracts may be managed with stronger glasses or lighting, surgery to replace the cloudy lens with an artificial one is the most effective treatment and is commonly performed with high success rates.

Find out more about cataract medication @ https://www.delveinsight.com/report-store/cataract-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Cataract Treatment Analysis: Drug Profile
NPI 002: Nacuity Pharmaceuticals
Nacuity Pharmaceuticals has developed an intravitreal implant prototype containing NPI-002, a small antioxidant molecule designed to slow cataract progression, along with a proprietary injector. The company has completed non-clinical testing, obtained HREC approval, and plans to begin a Phase 1/2 clinical trial in Australia for NPI-002 in the fourth quarter of 2021.

CGT 1507: CGeneTech
CGT 1507 is a small molecule targeting proteolytic enzymes. Currently in the pre-clinical stage, this drug is being developed for the treatment of cataracts.

Research Programme: Ocular Therapeutics - Plex Pharmaceuticals
Plex Pharmaceuticals is developing CAP 1160, a small molecule targeting HSP27 heat-shock protein modulators, as part of its ocular therapeutics program. The molecule aims to enhance the chaperone-like activity (CLA) of alpha-crystallin (AC), a key protein in the eye lens, to reverse, slow, or prevent cataract formation. By improving AC's CLA, Plex aims to protect damaged lens proteins and prevent aggregation, which is critical for maintaining lens transparency and preventing cataract development.

Learn more about the novel and emerging cataract pipeline therapies @ https://www.delveinsight.com/report-store/cataract-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Cataract Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

By Molecule Type
• Oligonucleotide
• Peptide
• Small molecule

Scope of the Cataract Pipeline Report
• Coverage: Global
• Key Cataract Companies: Nacuity Pharmaceuticals, CGeneTech, Plex Pharmaceuticals, and others.
• Key Cataract Pipeline Therapies: NPI 002, CGT 1507, Research programme: ocular therapeutics, and others.

Dive deep into rich insights for drugs used for cataract treatment; visit @ https://www.delveinsight.com/report-store/cataract-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Cataract Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Cataract Pipeline Therapeutics
6. Cataract Pipeline: Late-Stage Products (Phase III)
7. Cataract Pipeline: Mid-Stage Products (Phase II)
8. Cataract Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.